Transpire Bio announces agreement with Recipharm for the development of an inhaled medicine

Transpire Bio, a development-stage pharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, has announced a definitive agreement with Recipharm to develop TRB-1 and TRB-2, inhaled medicines for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). TRB-1 and TRB-2, the first products developed by Transpire Bio, will be indicated for the treatment of asthma and COPD, intended for advanced markets.

“Our mission is to improve access to important, life-saving inhaled therapies, and to introduce new inhaled therapies to help address areas of significant unmet medical need”, said Dr. Xian-Ming Zeng, CEO of Transpire Bio. “TRB-1 and TRB-2 are our first offerings in development which will help improve access for potentially millions of patients. We are very excited to be working with Recipharm to advance these important medicines.”

Jean-Francois Hilaire, Executive Committee Member, Head of Business Unit Advanced Delivery Systems added, “Recipharm is very pleased to be leveraging its broad experience and expertise in developing and commercializing inhalation technologies and products in support of the development and advancement of Transpire Bio’s TRB-1 and TRB-2 respiratory products. We look forward to the collaboration.”

According to statistics from the World Health Organization, asthma affected approximately 262 million people in 2019, and accounted for approximately 455,000 deaths. COPD was the third-leading cause of death in 2019, with approximately 3.2 million lives lost.


About Transpire Bio

Transpire Bio Inc. is a US-based, development-stage biopharmaceutical company headquartered in Miami, Florida. The mission of Transpire Bio is to harness the power of inhaled drug delivery to improve patient access to important therapies and develop treatments for serious diseases where therapeutic options are significantly lacking. Transpire Bio develops multiple inhaled approaches, including metered-dose inhalers, soft-mist inhalers, and dry powder inhalers.

For more information, please visit, [email protected], +1 954.315.0224.


About Recipharm

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden.

For more information on Recipharm and our services, please visit


Contact information:

Marcus Smith, Head of Communications at Recipharm, [email protected]
Sunny Zhao, Manager at Transpire Bio, [email protected]